We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:GEVA | NASDAQ | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 238.60 | 0.00 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
BAKER FELIX |
2. Issuer Name
and
Ticker or Trading Symbol
SYNAGEVA BIOPHARMA CORP [ GEVA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) __ X __ Other (specify below) Former 10% owner and Director |
667 MADISON AVENUE, 21ST FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY US 10065 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Comon Stock | 6/22/2015 | D | 200526 (1) | D | (2) | 0 | D | |||
Comon Stock | 6/22/2015 | D | 143462 | D | (2) | 0 | I | See Footnotes (3) (11) | ||
Comon Stock | 6/22/2015 | D | 12250 | D | (2) | 0 | I | See Footnotes (4) (11) | ||
Comon Stock | 6/22/2015 | D | 12250 | D | (2) | 0 | I | See Footnotes (5) (11) | ||
Comon Stock | 6/22/2015 | D | 12250 | D | (2) | 0 | I | See Footnotes (6) (11) | ||
Comon Stock | 6/22/2015 | D | 680187 | D | (2) | 0 | I | See Footnotes (7) (11) | ||
Comon Stock | 6/22/2015 | D | 12250 | D | (2) | 0 | I | See Footnotes (8) (11) | ||
Comon Stock | 6/22/2015 | D | 12250 | D | (2) | 0 | I | See Footnotes (9) (11) | ||
Comon Stock | 6/22/2015 | D | 9184771 | D | (2) | 0 | I | See Footnotes (10) (11) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Non-Qualified Stock Option (right to buy) | $11.35 | 6/22/2015 | D | 3000 | 9/22/2011 | 9/22/2020 | Common Stock | 3000 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $10.1 | 6/22/2015 | D | 2750 | 7/21/2010 | 7/21/2019 | Common Stock | 2750 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $20.6 | 6/22/2015 | D | 2750 | 6/26/2009 | 6/26/2018 | Common Stock | 2750 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $25 | 6/22/2015 | D | 2750 | 8/14/2008 | 8/14/2017 | Common Stock | 2750 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $33.7 | 6/22/2015 | D | 2250 | 8/9/2007 | 8/9/2016 | Common Stock | 2250 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $52.85 | 6/22/2015 | D | 2250 | 8/9/2006 | 8/9/2015 | Common Stock | 2250 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $80.35 | 6/22/2015 | D | 7500 | 6/4/2015 | 6/4/2024 | Common Stock | 7500 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $40.32 | 6/22/2015 | D | 7500 | 6/6/2013 | 6/5/2023 | Common Stock | 7500 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $40.74 | 6/22/2015 | D | 7500 | 6/27/2012 | 6/27/2022 | Common Stock | 7500 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $23 | 6/22/2015 | D | 15000 | (16) | 12/19/2021 | Common Stock | 15000 | (12) | 0 | I | See Footnote (13) | |||
Non-Qualified Stock Option (right to buy) | $11.35 | 6/22/2015 | D | 3000 | 9/22/2011 | 9/22/2020 | Common Stock | 3000 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $10.1 | 6/22/2015 | D | 2500 | 7/21/2010 | 7/21/2019 | Common Stock | 2500 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $20.6 | 6/22/2015 | D | 2500 | 6/26/2009 | 6/26/2018 | Common Stock | 2500 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $25 | 6/22/2015 | D | 2500 | 8/14/2008 | 8/14/2017 | Common Stock | 2500 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $33.7 | 6/22/2015 | D | 2250 | 8/9/2007 | 8/9/2016 | Common Stock | 2250 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $52.85 | 6/22/2015 | D | 2250 | 8/9/2006 | 8/9/2015 | Common Stock | 2250 | (12) | 0 | I | See Footnote (14) | |||
Non-Qualified Stock Option (right to buy) | $80.35 | 6/4/2014 | D | 7500 | 6/4/2015 | 6/4/2024 | Common Stock | 7500 | (12) | 0 | I | See Footnote (15) | |||
Non-Qualified Stock Option (right to buy) | $40.32 | 6/6/2013 | D | 7500 | 6/6/2013 | 6/5/2023 | Common Stock | 7500 | (12) | 0 | I | See Footnote (15) | |||
Non-Qualified Stock Option (right to buy) | $40.74 | 6/27/2012 | D | 7500 | 6/27/2012 | 6/27/2022 | Common Stock | 7500 | (12) | 0 | I | See Footnote (15) | |||
Non-Qualified Stock Option (right to buy) | $23 | 12/20/2011 | D | 15000 | (16) | 12/19/2021 | Common Stock | 15000 | (12) | 0 | I | See Footnote (15) |
Remarks:
Pursuant to the consummation of the merger, pursuant to the Merger Agreement (as defined in footnote 2) on June 22, 2015 Felix J. Baker tendered his resignation as a director of Synageva Biopharma Corp. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
BAKER FELIX
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
Baker Bros. Advisors (GP) LLC
667 MADISION AVENUE 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
BAKER BROS. ADVISORS LP
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
BAKER JULIAN
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
Baker Brothers Life Sciences LP
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
14159, L.P.
667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
667, L.P.
667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
Baker/Tisch Investments, LP
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
Baker Bros. Investments, L.P.
667 MADISON AVENUE NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director | |
Baker Bros. Investments II, L.P.
667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065 |
|
|
|
Former 10% owner and Director |
Signatures
|
||
/s/ Felix J. Baker | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors (GP) LLC Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Julian C. Baker | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing Title: President /s/ | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to Baker Tisch Investments, L.P. , pursuant to authority granted by Baker Tisch Capital, L.P., GP to Baker Tisch Investments, L.P. Name: Scott L. Lessing Title: President /s/ | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to Baker Bros. Investments, L.P., pursuant to authority granted by Baker Bros. Capital, L.P., GP to Baker Bros. Investments, L.P. Name: Scott L. Lessing Title: President /s/ | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to Baker Bros. Investments II, L.P., pursuant to authority granted by Baker Bros. Capital, L.P., GP to Baker Bros. Investments II, L.P. Name: Scott L. Lessing Title: President /s/ | 6/23/2015 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions